Supplement Maker Lands FDA Warning Letter for GMP Violations, Drug-like Claims By Sam | February 7, 2017 A California supplement maker is drawing scrutiny from the FDA for violating GMP regulations and misbranding products as drugs. Source: Drug Industry Daily Posted in Drug Industry Daily